PharmaEssentia: New ET Indication Aims for August Approval, AOP Arbitration Hopes for Settlement
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
PharmaEssentia expects revenue and profit growth to surpass last year, driven by strong sales of its blood cancer drug Ropeg and anticipated US FDA approval in August for a new indication, Essential Thrombocythemia (ET). The company is also actively pursuing a settlement in its arbitration with European distributor AOP.